Immunodeficient mouse models of lymphoid tumors

International Journal of Hematology

Volumn 77, Issue 4, 2003, Pages 336-341

  Imada, Kazunori ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Animal model; ATL; Lymphoma; NOD SCID mouse; SCID mouse

Indexed keywords

ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CARCINOGENESIS; COMBINED IMMUNODEFICIENCY; HUMAN; IN VIVO STUDY; LYMPHATIC SYSTEM TUMOR; LYMPHOMA; MOUSE STRAIN; NONHUMAN; POSTOPERATIVE PERIOD; T CELL LEUKEMIA; T LYMPHOCYTE; TUMOR GROWTH; XENOGRAFT; XENOTRANSPLANTATION;

EID: 0141680990     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982640     Document Type: Article

References (52)

1. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature. 1983;301:527-530.
2. Flavell DJ. Modelling human leukemia and lymphoma in severe combined immunodeficient (SCID) mice: practical applications. Hematol Oncol. 1996;14:67-82.
3. Bankert RB, Hess SD, Egilmez NK. SCID mouse models to study human cancer pathogenesis and approaches to therapy: potential, limitations, and future directions. Front Biosci. 2002;7:c44-62.
4. Greiner DL, Shultz LD, Yates J, et al. Improved engraftment of human spleen cells in NOD/LtSz-scid/scid mice as compared with C.B-17-scid/scid mice. Am J Pathol. 1995;146:888-902.
5. Shultz LD, Schweitzer PA, Christianson SW, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol. 1995;154:180-191.
6. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50:481-492.
7. Uchiyama T. Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu Rev Immunol. 1997;15:15-37.
8. Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol. 2001;19:475-496.
9. Kondo A, Imada K, Hattori T, et al. A model of in vivo cell proliferation of adult T-cell leukemia. Blood. 1993;82:2501-2509.
10. Feuer G, Zack JA, Harrington WJ Jr, et al. Establishment of human T-cell leukemia virus type I T-cell lymphomas in severe combined immunodeficient mice. Blood. 1993;82:722-731.
11. Imada K, Takaori-Kondo A, Akagi T, et al. Tumorigenicity of human T-cell leukemia virus type I-infected cell lines in severe combined immunodeficient mice and characterization of the cells proliferating in vivo. Blood. 1995;86:2350-2357.
12. Imada K, Takaori-Kondo A, Sawada H, et al. Serial transplantation of adult T cell leukemia cells into severe combined immunodeficient mice. Jpn J Cancer Rev. 1996;87:887-892.
13. Takaori-Kondo A, Imada K, Yamamoto I, et al. Parathyroid hormone-related protein-induced hypercalcemia in SCID mice engrafted with adult T-cell leukemia cells. Blood. 1998;91:4747-4751.
14. Bunn PA Jr, Schechter GP, Jaffe E, et al. Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med. 1983;309:257-264.
15. Johannessen I, Crawford DH. In vivo models for Epstein-Barr virus (EBV)-associated B cell lymphoproliferative disease (BLPD). Rev Med Virol. 1999;9:263-277.
16. Mosier DE, Gulizia RJ, Baird SM, Wilson DB. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature. 1988;335:256-259.
17. Rowe M, Young LS, Crocker J, Stokes H, Henderson S, Rickinson AB. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med. 1991;173:147-158.
18. Mosier DE. Viral pathogenesis in hu-PBL-SCID mice. Semin Immunol. 1996;8:255-262.
19. Picchio GR, Kobayashi R, Kirven M, Baird SM, Kipps TJ, Mosier DE. Heterogeneity among Epstein-Barr virus-seropositive donors in the generation of immunoblastic B-cell lymphomas in SCID mice receiving human peripheral blood leukocyte grafts. Cancer Res. 1992;52:2468-2477.
20. Amadori A, Veronese ML, Mazza MR, et al. Lymphoma induction by human B cells in scid mice. Leukemia. 1992;6(suppl 3):23S-25S.
21. Veronese ML, Veronesi A, D'Andrea E, et al. Lymphoproliferative disease in human peripheral blood mononuclear cell-injected SCID mice, I: T lymphocyte requirement for B cell tumor generation. J Exp Med. 1992;176:1763-1767.
22. Johannessen I, Asghar M, Crawford DH. Essential role for T cells in human B-cell lymphoproliferative disease development in severe combined immunodeficient mice. Br J Haematol 2000;109:600-610.
23. Johannessen I, Perera SM, Gallagher A, Hopwood PA, Thomas JA, Crawford DH. Expansion in scid mice of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease biopsy material. J Gen Virol. 2002;83:173-178.
24. Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES. Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. Int J Cancer. 1990;45:481-485.
25. Waller EK, Kamel OW, Cleary ML, et al. Growth of primary T-cell non-Hodgkin's lymphomata in SCID-hu mice: requirement for a human lymphoid microenvironment. Blood. 1991;78:2650-2665.
26. Itoh T, Shiota M, Takanashi M, et al. Engraftment of human non-Hodgkin lymphomas in mice with severe combined immunodeficiency. Cancer. 1993;72:2686-2694.
27. Kapp U, Wolf J, von Kalle C, et al. Preliminary report: growth of Hodgkin's lymphoma derived cells in immune compromised mice. Ann Oncol. 1992;3(suppl 4):21-23.
28. Bargou RC, Mapara MY, Zugck C, et al. Characterization of a novel Hodgkin cell line, HD-MyZ, with myelomonocytic features mimicking Hodgkin's disease in severe combined immunodeficient mice. J Exp Med. 1993;177:1257-1268.
29. Wolf J, Kapp U, Bohlen H, et al. Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood 1996;87:3418-3428.
30. Kapp U, Wolf J, Hummel M, et al. Hodgkin's lymphoma-derived tissue serially transplanted into severe combined immunodeficient mice. Blood. 1993;82:1247-1256.
31. Hudson WA, Li Q, Le C, Kersey JH. Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects. Leukemia. 1998;12:2029-2033.
32. Fusetti L, Pruneri G, Gobbi A, et al. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production. Cancer Res. 2000;60:2527-2534.
33. Phillips KE, Herring B, Wilson LA, et al. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction. Cancer Res. 2000;60:6977-6984.
34. Liu Y, Dole K, Stanley JR, et al. Engraftment and tumorigenesis of HTLV-1 transformed T cell lines in SCID/bg and NOD/SCID mice. Leuk Res. 2002;26:561-567.
35. Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res. 2002;62:1083-1086.
36. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999;59:728-733.
37. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood. 1997;90:3167-3172.
38. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood. 1999;94:3334-3339.
39. Bertolini F, Fusetti L, Mancuso P, et al. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood. 2000;96:282-287.
40. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
41. Lentzsch S, Rogers MS, LeBlanc R, et al. S-3-Amino-phthalimidoglutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res. 2002;62:2300-2305.
42. Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. 1994;83:2045-2056.
43. Tian ZG, Longo DL, Funakoshi S, et al. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Cancer Res. 1995;55:5335-5341.
44. Wahl AF, Klussman K, Thompson JD, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 2002;62:3736-3742.
45. Nagy ZA, Hubner B, Lohning C, et al. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat Med. 2002;8:801-807.
46. Barth S, Huhn M, Matthey B, et al. Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA′ demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice. Int J Cancer. 2000;86:718-724.
47. Barth S, Huhn M, Matthey B, et al. Ki-4(scFv)-ETA′, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood. 2000;95:3909-3914.
48. Boyle TJ, Berend KR, DiMaio JM, Coles RE, Via DF, Lyerly HK. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. Surgery. 1993;114:218-225.
49. Lacerda JF, Ladanyi M, Louie DC, Fernandez JM, Papadopoulos EB, O'Reilly RJ. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice. J Exp Med. 1996;183:1215-1228.
50. Cotter FE, Waters J, Cunningham D. Human Bcl-2 antisense therapy for lymphomas. Biochim Biophys Acta. 1999;1489:97-106.
51. Cotter FE, Johnson P, Hall P, et al. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene. 1994;9:3049-3055.
52. Mohammad R, Abubakr Y, Dan M, et al. Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma. Clin Cancer Res. 2002;8:1277-1283.